This FAQ delves into the promising trends and developments in Infectious Diseases research. DOWNLOAD THE FULL WHITEPAPER HERE

How has the global landscape of infectious disease clinical trials evolved in recent years?

In the twenty-first century, there has been a significant increase in the prevalence of infectious diseases, necessitating an intensified focus on clinical trials to develop effective prevention and control measures. Over the last five years, the number of industry-initiated clinical trials for infectious diseases has grown substantially. The trial landscape has experienced high compound annual growth rates (CAGR) from 2018 to 2022, with the total number of trials increasing from over 700 in 2018 to more than 1,000 by 2022. This escalation underscores the global commitment to comprehensively addressing infectious diseases and finding innovative solutions.

Which regions have emerged as major centers for infectious disease research and clinical trials?

Mainland China, the EU5 countries (comprising Germany, France, the United Kingdom, Italy, and Spain), and the United States have established themselves as key hubs for infectious disease research and clinical trials. These regions have shown a strong dedication to advancing our understanding of infectious diseases and developing novel therapies. The Asia-Pacific region in particular has excelled not only in the sheer volume of studies but also in patient recruitment, resulting in shorter enrollment durations. This competitive advantage has accelerated data collection and the development of therapies and vaccines.

What are the primary targets of infectious disease clinical trials, and how have they evolved in recent years?

Viral infections have been the primary focus of infectious disease clinical trials in recent years. Notably, viral infections such as COVID-19, HIV, hepatitis, RSV, Zika, and Ebola have gained prominence due to the COVID-19 pandemic. The Asia-Pacific region has taken the lead in conducting research on these viral infections. Bacterial infections, often complicated by antibiotic resistance, as well as fungal and protozoan infections, have also received significant attention in clinical research. While small molecules have traditionally dominated these studies, biologic medicines are gaining ground. Vaccines and monoclonal antibodies have shown promise as leading biologic modalities. Additionally, advanced technologies like mRNA and siRNA therapeutics are garnering substantial interest, especially following the rapid development of COVID-19 mRNA vaccines.

How has venture capital financing contributed to infectious disease clinical research and development?

Venture capital financing has played a critical role in advancing global infectious disease clinical research and development. Funding estimates have increased significantly, rising from $2.8 million through 81 deals in 2018 to approximately $4 million over 96 deals in 2022. The United States and China have emerged as leaders in securing such financing, maintaining their pivotal roles in the global landscape of infectious disease research.

What does the heightened focus on infectious disease clinical trials mean for global health security and biodefense?

The increased focus on infectious disease clinical trials underscores the paramount importance of global collaboration in addressing infectious disease threats. The COVID-19 pandemic has highlighted the necessity for a coordinated global effort to combat the evolving challenges posed by infectious diseases. Staying informed about current trends, regional disparities, technological advancements, and financing dynamics is crucial for shaping best practices in trial execution and fortifying our collective defenses against infectious diseases.